Prostate Cancer, Version 1.2016.

Published

Journal Article

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

Full Text

Duke Authors

Cited Authors

  • Mohler, JL; Armstrong, AJ; Bahnson, RR; D'Amico, AV; Davis, BJ; Eastham, JA; Enke, CA; Farrington, TA; Higano, CS; Horwitz, EM; Hurwitz, M; Kane, CJ; Kawachi, MH; Kuettel, M; Lee, RJ; Meeks, JJ; Penson, DF; Plimack, ER; Pow-Sang, JM; Raben, D; Richey, S; Roach, M; Rosenfeld, S; Schaeffer, E; Skolarus, TA; Small, EJ; Sonpavde, G; Srinivas, S; Strope, SA; Tward, J; Shead, DA; Freedman-Cass, DA

Published Date

  • January 2016

Published In

Volume / Issue

  • 14 / 1

Start / End Page

  • 19 - 30

PubMed ID

  • 26733552

Pubmed Central ID

  • 26733552

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2016.0004

Language

  • eng

Conference Location

  • United States